6-chloro-4-(methylthio)pyridazin-3-amine | 896740-03-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 6-chloro-4-(methylthio)pyridazin-3-amine
• 英文别名: 3-Pyridazinamine, 6-chloro-4-(methylthio)-；6-chloro-4-methylsulfanylpyridazin-3-amine
• CAS: 896740-03-7
• 化学式: C₅H₆ClN₃S
• 分子量: 175.642
• InChiKey: IXQQPGRKXRNRRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  77.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氨基-4-溴-6-氯哒嗪 、 sodium thiomethoxide 在 氩 、 crude product 、 silica gel 、 methanol diethyl ether 作用下， 以 1,4-二氧六环 为溶剂， 以providing the title compound (1.57 g, 37%) as off-white solid的产率得到6-chloro-4-(methylthio)pyridazin-3-amine
  参考文献：
  名称：

  TRIAZOLO COMPOUNDS

  摘要：

  本发明涉及式（I）化合物及其用于治疗神经系统疾病的用途。

  公开号：

  US20150232472A1

文献信息

• [EN] TRIAZOLO COMPOUNDS<br/>[FR] COMPOSÉS TRIAZOLO
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014072261A1

  公开（公告）日：2014-05-15

  The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.

  本发明涉及式(I)的化合物及其在治疗神经系统疾病中的应用。
• Condensed Imidazole Compound And Use Thereof
  申请人：Uchikawa Osamu

  公开号：US20080167314A1

  公开（公告）日：2008-07-10

  The present invention relates to a compound represented by the formula [I] wherein X 1 , X 2 and X 3 are each an optionally substituted CH or a nitrogen atom, and any one of X 1 , X 2 and X 3 is a nitrogen atom, X 4 is an optionally substituted CH, R 1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R 2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

  本发明涉及一种化合物，其表示为式[I]，其中X1、X2和X3分别是可选取代的CH或氮原子，且X1、X2和X3中的任意一个是氮原子，X4是可选取代的CH，R1是可选取代的苯基或可选取代的杂环基，R2是可选取代的吡啶-4-基、可选取代的吡啶-N-氧化物-4-基或可选取代的嘧啶-4-基，或其盐。该化合物具有优异的p38 MAP激酶抑制活性和MMP-13产生抑制活性，可用作预防或治疗炎症性疾病、自身免疫疾病、虚弱性疾病、骨关节退行性疾病、神经退行性疾病、血管疾病、肿瘤性疾病或感染性疾病的药物等。
• CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1832588A1

  公开（公告）日：2007-09-12

  The present invention relates to a compound represented by the formula [I] wherein X1, X2 and X3 are each an optionally substituted CH or a nitrogen atom, and any one of X1, X2 and X3 is a nitrogen atom, X4 is an optionally substituted CH, R1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R2 is an optionally substituted pyridin-4-yl group, an optionally substituted pyridine-N-oxide-4-yl group or an optionally substituted pyrimidin-4-yl group, or a salt thereof. The compound has superior p38 MAP kinase inhibitory activity and MMP-13 production inhibitory activity, and is useful as an agent for the prophylaxis or treatment and the like of an inflammatory disease, an autoimmune disease, a debilitating disease, an osteoarticular degenerative disease, a neurodegenerative disease, a vascular disease, a neoplastic disease or an infectious disease.

  本发明涉及一种由式 [I] 表示的化合物 其中X1、X2和X3各自为任选取代的CH或氮原子，且X1、X2和X3中的任一个为氮原子，X4为任选取代的CH，R1为任选取代的苯基或任选取代的杂环基团，R2为任选取代的吡啶-4-基团、任选取代的吡啶-N-氧化-4-基团或任选取代的嘧啶-4-基团，或其盐。该化合物具有优异的 p38 MAP 激酶抑制活性和 MMP-13 生成抑制活性，可用于预防或治疗炎症性疾病、自身免疫性疾病、衰弱性疾病、骨关节退行性疾病、神经退行性疾病、血管性疾病、肿瘤性疾病或传染性疾病等。
• US9617271B2
  申请人：——

  公开号：US9617271B2

  公开（公告）日：2017-04-11
• TRIAZOLO COMPOUNDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150232472A1

  公开（公告）日：2015-08-20

  The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders.

  本发明涉及式（I）化合物及其用于治疗神经系统疾病的用途。